MedTrace Logo

Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor

NCT01845675 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2017-04-13

No results posted yet for this study

Summary

Temozolomide or dacarbazine-based chemotherapy combined with endostatin have efficacy in well-differentiated pancreatic neuroendocrine tumor

Conditions

  • Advanced Well-differentiated Pancreatic Neuroendocrine Tumor

Interventions

DRUG

temozolomide or dacarbazine-based chemotherapy, endostatin

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2016-11-30
Completion
2017-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01845675 on ClinicalTrials.gov